Hypothesized role of pregnancy hormones on HER2+breast tumor development
Cruz, Giovanna I.; Martinez, Maria Elena; Natarajan, Loki; Wertheim, Betsy C.; Gago Dominguez, Manuela; Bondy, Melissa; Daneri-Navarro, Adrian; Mercedes Meza-Montenegro, Maria; Enrique Gutierrez-Millan, Luis; Brewster, Abenaa; Schedin, Pepper; Komenaka, Ian K.; Esteban Castelao, J.; Carracedo Álvarez, Ángel; Redondo Marey, Carmen Maria; Thompson, Patricia A.
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Identificadores![](/xmlui/themes/Mirage2//images/despl_identif.png)
Identificadores
Visualización o descarga de ficheros![](/xmlui/themes/Mirage2//images/despl_contenidos.png)
Visualización o descarga de ficheros
Fecha de publicación
2013Título de revista
BREAST CANCER RESEARCH AND TREATMENT
Tipo de contenido
Artigo
MeSH
Adult | Breast Neoplasms | Female | Gonadal Steroid Hormones | Hispanic Americans | Humans | Incidence | Logistic Models | Mexico | Middle Aged | Placental Hormones | Pregnancy | Premenopause | Receptor, ErbB-2 | Receptors, Estrogen | Receptors, Progesterone | Spain | United States | Young AdultResumen
Breast cancer incidence rates have declined among older but not younger women; the latter are more likely to be diagnosed with breast cancers carrying a poor prognosis. Epidemiological evidence supports an increase in breast cancer incidence following pregnancy with risk elevated as much as 10 years post-partum. We investigated the association between years since last full-term pregnancy at the time of diagnosis (</=10 or >10 years) and breast tumor subtype in a case series of premenopausal Hispanic women (n = 627). Participants were recruited in the United States, Mexico, and Spain. Cases with known estrogen receptor (ER), progesterone receptor (PR), and HER2 status, with one or more full-term pregnancies >/=1 year prior to diagnosis were eligible for this analysis. Cases were classified into three tumor subtypes according to hormone receptor (HR+ = ER+ and/or PR+; HR- = ER- and PR-) expression and HER2 status: HR+/HER2-, HER2+ (regardless of HR), and triple negative breast cancer. Case-only odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated for HER2+ tumors in reference to HR+/HER2- tumors. Participants were pooled in a mixed-effects logistic regression model with years since pregnancy as a fixed effect and study site as a random effect. When compared to HR+/HER2- cases, women with HER2+ tumors were more likely be diagnosed in the post-partum period of </=10 years (OR = 1.68; 95 % CI, 1.12-2.52). The effect was present across all source populations and independent of the HR status of the HER2+ tumor. Adjusting for age at diagnosis (</=45 or >45 years) did not materially alter our results (OR = 1.78; 95 % CI, 1.08-2.93). These findings support the novel hypothesis that factors associated with the post-partum breast, possibly hormonal, are involved in the development of HER2+ tumors.
![](/xmlui/themes/Mirage2//images/final_lines.png)